LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
BCIQ Data Coverage
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
3rd Biotech CEO & Investor Reception
East-West Biopharma Summit 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
Jun 1, 2024
Data Byte
EMA’s CHMP recommends new indications for Dupixent, Skyrizi
May decisions also include CStone’s PD-1 inhibitor and Pfizer’s
Factor IX
gene therapy
Read More
BioCentury
|
Mar 26, 2024
Deals
Deals Report: Week’s M&A includes AZ-Fusion, Novo Nordisk-Cardior
Plus: Intellia deciding to step back from co-developing
Factor-IX
therapy with Regeneron and GSK returns Sosei’s GPR35 agonist after deprioritization
Read More
BioCentury
|
Feb 22, 2023
Regulation
Feb. 21 Quick Takes: Crossovers back Hemab in $135M series B
Plus: FDA reviewing Onpattro for larger ATTR indication; EU gets first hemophilia B gene therapy; and updates from Merck, Pfizer and more
Read More
BioCentury
|
Jan 3, 2023
Data Byte
Hemophilia B competition builds with Pfizer gene therapy data
Different vectors lead to comparable improvements in bleeding in Phase III studies
Read More
BioCentury
|
Dec 13, 2022
Product Development
Dec. 12 Quick Takes: Setbacks at ASH for Adicet and Lava
Plus: Updates from Magenta, CSL, Hemgenix, Affimed, Kymera and more
Read More
BioCentury
|
Nov 22, 2022
Regulation
CSL pushes pricing limits with first hemophilia B gene therapy approval
CSL is setting a $3.5 million price for the first hemophilia B gene therapy to reach the market
Read More
BioCentury
|
Aug 8, 2022
Deals
Pfizer promises expanded global reach for sickle cell drug in $5.4B GBT takeout
Pharma gains rights to Oxbryta along with a sickle cell pipeline that could deliver $3B in peak sales
Read More
BioCentury
|
May 25, 2022
Finance
May 24 Quick Takes: Duke Street Bio debuts to develop PARP inhibitors
Plus Alvotech’s Stelara biosimilar demonstrates bioequivalence and updates from uniQure, CSL, Alpine and more
Read More
BioCentury
|
Dec 9, 2021
Product Development
Welcome win for gene therapy as uniQure hits mark in hemophilia B
uniQure and partner CSL to submit regulatory applications next half
Read More
BioCentury
|
Mar 29, 2021
Product Development
March 29 Quick Takes: Humanigen mAb meets COVID endpoint; plus Merck, Wave, Celldex, Ionis, Orphazyme and uniQure
Humanigen Inc. (NASDAQ:HGEN) shares rose 54% to $21.61 Monday after the company said top-line data showed lenzilumab improved survival without the need for mechanical ventilation in hospitalized
Read More
Items per page:
10
1 - 10 of 416